{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T15:03:05Z","timestamp":1690470185915},"reference-count":13,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2019,9,1]]},"DOI":"10.1248\/bpb.b19-00122","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T18:03:46Z","timestamp":1567274626000},"page":"1590-1595","source":"Crossref","is-referenced-by-count":1,"title":["The Prediction of the Area under the Curve and Clearance of Midazolam from Single-Point Plasma Concentration and Urinary Excretion in Healthy Volunteers"],"prefix":"10.1248","volume":"42","author":[{"given":"Motoyasu","family":"Miura","sequence":"first","affiliation":[{"name":"Departments of Pharmacy Practice & Science, School of Pharmaceutical Sciences, University of Shizuoka"},{"name":"Hospital Pharmacy, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Uchida","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy Practice & Science, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimako","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy Practice & Science, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Namiki","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy Practice & Science, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Schwartz JB. The influence of sex on pharmacokinetics. <i>Clin. Pharmacokinet.<\/i>, <b>42<\/b>, 107\u2013121 (2003).","DOI":"10.2165\/00003088-200342020-00001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Rodighiero V. Effects of liver disease on pharmacokinetics. An update. <i>Clin. Pharmacokinet.<\/i>, <b>37<\/b>, 399\u2013431 (1999).","DOI":"10.2165\/00003088-199937050-00004"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Dresser GK, Spence JD, Bailey DG. Pharmacokinetic\u2013pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. <i>Clin. Pharmacokinet.<\/i>, <b>38<\/b>, 41\u201357 (2000).","DOI":"10.2165\/00003088-200038010-00003"},{"key":"4","unstructured":"4) Thummel KE, Shen DD, Podoll TD, <i>et al.<\/i> Use of midazolam as a human cytochrome P450 3A probe: I. <i>In vitro<\/i>\u2013<i>in vivo<\/i> correlations in liver transplant patients. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>271<\/b>, 549\u2013556 (1994)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. <i>Clin. Pharmacol. Ther.<\/i>, <b>72<\/b>, 718\u2013728 (2002).","DOI":"10.1067\/mcp.2002.129068"},{"key":"6","unstructured":"6) Kim JS, Nafziger AN, Tsunoda SM, Choo EE, Streetman DS, Kashuba AD, Kulawy RW, Beck DJ, Rocci ML Jr, Wilkinson GR, Greenblatt DJ, Bertino JS Jr. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. <i>J. Clin. Pharmacol.<\/i>, <b>42<\/b>, 376\u2013382 (2002)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Chaobal HN, Kharasch ED. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. <i>Clin. Pharmacol. Ther.<\/i>, <b>78<\/b>, 529\u2013539 (2005).","DOI":"10.1016\/j.clpt.2005.08.004"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Misaka S, Uchida S, Imai H, Inui N, Nishio S, Ohashi K, Watanabe H, Yamada S. Pharmacokinetics and pharmacodynamics of low doses of midazolam administered intravenously and orally to healthy volunteers. <i>Clin. Exp. Pharmacol. Physiol.<\/i>, <b>37<\/b>, 290\u2013295 (2010).","DOI":"10.1111\/j.1440-1681.2009.05285.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Yan D, Yang Y, Uchida S, Misaka S, Luo J, Takeuchi K, Inui N, Yamada S, Ohashi K, Watanabe H. Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers. <i>Naunyn Schmiedebergs Arch. Pharmacol.<\/i>, <b>377<\/b>, 629\u2013636 (2008).","DOI":"10.1007\/s00210-007-0217-z"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. <i>J. Pharmacokinet. Biopharm.<\/i>, <b>9<\/b>, 503\u2013512 (1981).","DOI":"10.1007\/BF01060893"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Masters JC, Harano DM, Greenberg HE, Tsunoda SM, Jang IJ, Ma JD. Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping. <i>Ther. Drug Monit.<\/i>, <b>37<\/b>, 84\u201389 (2015).","DOI":"10.1097\/FTD.0000000000000116"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Mueller SC, Drewelow B. Evaluation of limited sampling models for prediction of oral midazolam <i>AUC<\/i> for CYP3A phenotyping and drug interaction studies. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>69<\/b>, 1127\u20131134 (2013).","DOI":"10.1007\/s00228-012-1437-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Streetman DS, Kashuba AD, Bertino JS Jr, Kulawy R, Rocci ML Jr, Nafziger AN. Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. <i>Pharmacogenetics<\/i>, <b>11<\/b>, 349\u2013355 (2001).","DOI":"10.1097\/00008571-200106000-00010"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/9\/42_b19-00122\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T23:20:42Z","timestamp":1567812042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/9\/42_b19-00122\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b19-00122","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}